A5039381725- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Ubiquitin and proteasome pathways
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Fungal Infections and Studies
- Epigenetics and DNA Methylation
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Cerebrovascular and Carotid Artery Diseases
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Stroke Rehabilitation and Recovery
- Chronic Myeloid Leukemia Treatments
- HIV/AIDS drug development and treatment
- CRISPR and Genetic Engineering
- Neuroblastoma Research and Treatments
- Myasthenia Gravis and Thymoma
- DNA Repair Mechanisms
- Acute Ischemic Stroke Management
- Advancements in Semiconductor Devices and Circuit Design
- Integrated Circuits and Semiconductor Failure Analysis
Universitätsmedizin Göttingen
2019-2025
University Hospital and Clinics
2024
Charité - Universitätsmedizin Berlin
2024
University Medical Center
2024
University Hospital Cologne
2024
University of Helsinki
2024
University Hospital Leipzig
2024
University of Göttingen
2024
Genmab (United States)
2023
Janssen (Belgium)
2023
Abstract T-cell large granular lymphocytic leukemia (T-LGLL) is a rare hematologic neoplasm characterized by clonal expansion of CD3 + cytotoxic T lymphocytes and highly heterogeneous clinical course. Conventional therapy primarily includes immunosuppressive regimen. However, optimal front-line approaches still need to be defined refractory disease remains challenge. Thus, we here aimed explore functional dependencies T-LGLL as basis for personalized therapeutic strategies. We performed...
<i>Objective:</i> To assess the safety of tissue-type plasminogen activator (t-PA) plus clomethiazole in patients with acute ischemic stroke and determine feasibility combination therapy. <i>Background:</i> Clomethiazole is a neuroprotectant that appeared to improve outcome clinical deficits major (total anterior circulation syndrome [TACS]) previous study, Acute Stroke Study (CLASS). Combining such as thrombolysis may augment beneficial effects two agents. CLASS–t-PA (CLASS-T) was pilot...
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from cells, can mimic both acute leukemia and aggressive T-cell lymphoma. Therapy of this highly hematological disease should be initiated as soon possible, especially in light novel targeted therapies that have become available. However, differential diagnosis BPDCN remains challenging. This retrospective study aimed to highlight the challenges timely diagnoses BPDCN. We documented diagnostic clinical...
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines, but real-world data scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes of 70 patients with r/r DLBCL treated glofitamab as part compassionate use patient program in DACH region (Germany, Austria, Switzerland). The median number lines was four, 71% having received CAR-T therapy,...
Abstract Background Multi-omics studies have shown a high and lack of common driver mutations in most thymomas (TH) thymic carcinomas (TC) that hamper the development novel treatment approaches. However, deregulation apoptosis has been proposed as hallmark TH TC. BH3 profiling can be utilized to study readiness living cancer cells undergo their dependency on pro-survival BCL-2 family proteins. Methods We screened cohort 62 TC patient samples for expression proteins used cell line 1889c...
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing small TP53-mutated clone. As third-line therapy, patient treated CAR-T cells, which resulted in complete remission. However, this treatment also led expansion clone and therapy-related myelodysplasia complex aberrant karyotype. This may serve as paradigmatic example clonal...
Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied. Here we analyzed the outcomes CAR-T r/r DLBCL patients CNS compared them without disease. Retrospective monocentric comparative analysis patient cohort treated therapy: 15 versus 65 involvement. Overall response rates (80% 80%; P = 1.0), progression-free survival (P 0.157), overall...
Intraocular lymphoma (IOL) presents a real challenge in daily diagnostics. Cyto- and/or histopathology of vitreous body represent the diagnostic cornerstones. Yet, false negative results remain common. Therefore, we analyzed significance flow cytometry (FC) within workup algorithm IOL and compared its sensitivity with obtained from routine cytopathology molecular genetics; Methods: Seven patients undergoing vitrectomy due to suspected were investigated by FC parallel and, if available,...
Second allogeneic stem cell transplantation (allo-SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post-allo-SCT2 remain high and effective anti-relapse strategies predictive biomarkers to be defined. We here analyzed cohort of 41 AML undergoing allo-SCT2 in our center. Allo-SCT2 induced third hematologic complete remission (CR) 37 pts, at costs 36% non-relapse mortality rate. Furthermore, 19 pts...
<title>Abstract</title> Mature T-cell lymphomas and leukemias (mTCL) comprise a clinically genetically heterogeneous group of lymphoid malignancies. Most subtypes peripheral leukemic malignancies show an aggressive clinical course poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage recent progress deciphering the genetic basis mTCL, we generated comprehensive database alterations from >1 800 patients with mTCL utilized bioinformatic...
The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important role high-risk patients disease progression and transformation into acute myeloid leukemia (AML), knowledge about lower-risk MDS (LR-MDS) is limited due lack robust longitudinal data considering long clinically stable courses disease. In this retrospective analysis, we delineate...
Allogeneic stem cell transplantation (alloSCT) represents a curative option for patients with relapsed/refractory (r/r) aggressive lymphomas. We compared outcomes of alloSCT in r/r PTCL and DLBCL pts (
Abstract T-cell large granular lymphocytic leukemia (T-LGL) is a rare hematologic neoplasm characterized by clonal expansion of CD3+ cytotoxic T lymphocytes and highly heterogeneous clinical course. Conventional therapy primarily includes immunosuppressive regimen. However, optimal front-line approaches still need to be defined refractory disease remains challenge. Thus, we here aimed explore functional dependencies T-LGL as basis for personalized therapeutic strategies. We performed...
Background: Mutations in TP53 are associated with poor outcome pts myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This holds also true for allogeneic stem cell transplantation (Lindsley et al, NEJM, 2017). Regarding hypomethylating agents, it was suggested that mutations preferentially respond to decitabine (Welch 2016), although more recent studies suggest response azacitidine (AZA) (Döhner Leukemia, 2018). Aims: Our aim retrospectively study real life data terms of AZA...